Loading SAILIFE price...
Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 6 Aug 2026), sales rose 11.7% from a year earlier to Rs 554 cr and profit rose 21.2% to Rs 73.3 cr.
Nothing in the filings we hold crosses one of our rules yet. Each rule needs a few complete years of results, so recently listed companies often show nothing here.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 6 results, the share rose on 3 and fell on 3, and moved by 3% or more on 4.
Q1 FY27: results filed 6 Aug 2026. The share went from its close on 5 Aug 2026 to its close on 7 Aug 2026 -2.09%.
| Measure | FY25 | FY26 |
|---|---|---|
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | 12.5% | 18.1% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | 0.06x | 0.04x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 3,626 Cr of assets. Its owners funded 68% of that and borrowings 3%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs 509 Cr, spent Rs 593 Cr on plant and equipment, and cash fell by Rs 9 Cr over the year.
Rs 100 or more means every rupee of reported profit arrived as cash.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.17 L cr | 34.5x | 5.0x | 14.4% | 17.9% | 0.05 | 20.2% | +10.5% | 0.94% |
| DIVISLAB Divi's Laboratories Limited | 2.40 L cr | 82.1x | 14.3x | 17.4% | 19.0% | 0.00 | 26.1% | +27.8% | 0.33% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.73 L cr | 76.9x | 9.4x | 11.4% | - | 0.76 | 12.1% | +50.8% | 0.74% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.16 L cr | 25.9x | 4.3x | 15.5% | 19.2% | 0.40 | 16.1% | +22.0% | 0.96% |
| LAURUSLABS Laurus Labs Limited | 1.11 L cr | 101.8x | 21.0x | 20.1% | 19.7% | 0.44 | 15.0% | +29.1% | 0.08% |
| CIPLA Cipla Limited | 1.09 L cr | 32.5x | 3.2x | 9.7% | 14.9% | 0.01 | 11.8% | +2.3% | 1.18% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.09 L cr | 39.0x | 2.8x | 7.0% | - | 0.15 | 8.3% | -1.5% | 0.61% |
| MANKIND Mankind Pharma Limited | 95,486 cr | 46.8x | 5.9x | 12.5% | 13.7% | 0.38 | 14.0% | +12.9% | 0.04% |
| AUROPHARMA Aurobindo Pharma Limited | 91,489 cr | 24.8x | 2.4x | 9.8% | 13.6% | 0.20 | 10.6% | +16.3% | 0.25% |
| LUPIN Lupin Limited | 89,616 cr | 16.2x | 4.0x | 24.7% | 28.4% | 0.26 | 18.5% | +32.0% | 0.61% |
| GLENMARK Glenmark Pharmaceuticals Limited | 62,812 cr | 35.0x | 6.0x | 17.1% | 16.2% | 0.00 | 10.1% | +23.1% | 0.22% |
| ALKEM Alkem Laboratories Limited | 60,134 cr | 27.9x | 4.3x | 15.4% | 18.8% | 0.11 | 14.6% | +10.9% | 1.02% |
| BIOCON Biocon Limited | 53,581 cr | 97.3x | 1.6x | 1.1% | 2.9% | 0.40 | 2.4% | +10.0% | 0.17% |
| IPCALAB IPCA Laboratories Limited | 49,182 cr | 37.5x | 6.1x | 14.4% | 16.4% | 0.07 | 13.6% | +20.8% | 0.11% |
| GLAND Gland Pharma Limited | 46,913 cr | 41.5x | 4.5x | 10.9% | 13.7% | 0.02 | 16.8% | +19.6% | 0.63% |
| AJANTPHARM Ajanta Pharma Limited | 42,381 cr | 37.2x | 9.4x | 25.1% | 29.4% | 0.05 | 19.6% | +24.8% | 0.83% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 41,436 cr | 38.8x | 18.3x | 46.8% | 55.4% | 0.00 | 27.0% | +16.6% | 1.72% |
| EMCURE Emcure Pharmaceuticals Limited | 33,767 cr | 33.4x | 6.8x | 20.5% | 25.1% | 0.24 | 10.5% | +22.9% | 0.17% |
| SAILIFE Sai Life Sciences Limited | 30,682 cr | 85.4x | 12.3x | 14.6% | 18.1% | 0.04 | 16.1% | +11.7% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 29,316 cr | 71.8x | 5.9x | 7.8% | 6.5% | 0.40 | 11.6% | +25.9% | 0.00% |
| PPLPHARMA Piramal Pharma Limited | 25,906 cr | - | 3.2x | -3.8% | 0.8% | 0.67 | -3.4% | +17.4% | 0.07% |
| RUBICON Rubicon Research Limited | 24,647 cr | 84.9x | 19.1x | 22.4% | 24.3% | 0.20 | 14.9% | - | 0.00% |
| NEULANDLAB Neuland Laboratories Limited | 24,582 cr | 49.1x | 13.1x | 26.6% | 23.1% | 0.10 | 21.0% | +119.2% | 0.06% |
| GRANULES Granules India Limited | 20,333 cr | 30.5x | 4.0x | 13.0% | 16.0% | 0.26 | 11.8% | +22.0% | 0.18% |
| COHANCE Cohance Lifesciences Limited | 17,735 cr | 115.6x | 4.5x | 2.6% | 4.8% | 0.04 | 3.9% | -23.1% | 0.00% |
| SHILPAMED Shilpa Medicare Limited | 17,620 cr | 59.0x | 6.8x | 11.5% | 12.4% | 0.25 | 17.7% | +44.9% | 0.06% |
| CAPLIPOINT Caplin Point Laboratories Limited | 17,282 cr | 26.1x | 4.8x | 18.7% | 22.0% | 0.00 | 29.6% | +19.6% | 0.26% |
| PFIZER Pfizer Limited | 16,869 cr | 30.9x | 4.0x | 17.5% | 22.9% | 0.00 | 28.6% | +8.3% | 4.46% |
| ONESOURCE Onesource Specialty Pharma Limited | 16,019 cr | - | 2.8x | -0.8% | 0.5% | 0.22 | -3.1% | +37.2% | 0.00% |
| ALIVUS Alivus Life Sciences Limited | 15,490 cr | 25.7x | 4.7x | 18.1% | 21.8% | 0.00 | 23.3% | +6.4% | 0.40% |
| ERIS Eris Lifesciences Limited | 15,318 cr | 23.5x | 3.9x | 17.1% | 15.7% | 0.59 | 20.6% | +13.0% | 0.00% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,129 cr | 174.2x | 17.3x | 19.4% | 25.5% | 0.00 | 7.0% | +29.7% | 0.53% |
| APLLTD Alembic Pharmaceuticals Limited | 15,064 cr | 21.7x | 2.6x | 12.2% | 12.8% | 0.24 | 8.9% | +25.7% | 1.44% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,805 cr | 42.3x | 2.1x | 5.0% | 6.4% | 0.45 | 4.1% | +17.3% | 0.54% |
| NATCOPHARM Natco Pharma Limited | 14,145 cr | 12.4x | 1.5x | 12.4% | 16.3% | 0.08 | 32.9% | -44.7% | 0.64% |
| CONCORDBIO Concord Biotech Limited | 13,717 cr | 50.3x | 6.8x | 13.5% | 16.6% | 0.00 | 24.6% | +26.2% | 0.82% |
| ACUTAAS Acutaas Chemicals Limited | 13,708 cr | 71.3x | 8.3x | 22.6% | 27.7% | 0.02 | 26.5% | +59.1% | 0.09% |
| MARKSANS Marksans Pharma Limited | 13,443 cr | 26.0x | 4.5x | 17.1% | 17.5% | 0.01 | 16.4% | +35.6% | 0.27% |
| CORONA CORONA Remedies Limited | 12,485 cr | 62.7x | 16.7x | 26.6% | 29.3% | 0.19 | 13.5% | - | 0.00% |
| AKUMS Akums Drugs and Pharmaceuticals Limited | 10,512 cr | 36.0x | 3.2x | 8.8% | 10.9% | 0.02 | 6.5% | +13.9% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Each bar is one quarter as filed with the exchange, newest on the right, so the seasonal shape of the business is visible rather than smoothed away. Hover any quarter for its full figures and the change against the same quarter a year earlier. Revenue and profit are drawn on separate scales because they differ by an order of magnitude; reading one against the other would be misleading.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.